SOTIO Biotech has dosed the first patients in the combination therapy arms of Phase I/II CLAUDIO-01 trial evaluating SOT102 for treating gastric and pancreatic cancer.

The first-in-human, multicentre, open-label study is being carried out at centres in Europe and the US.

It will assess the preliminary efficacy and safety of SOT102 along with the current standard of care as a first-line cancer treatment.

SOT102 will be evaluated in combination with mFOLFOX plus nivolumab in the gastric cancer arm, while in the pancreatic cancer arm, it will be assessed along with Nab-paclitaxel and gemcitabine.

To date, no dose-limiting toxicities were reported during the study.

SOTIO Biotech CEO Radek Spisek said: “The initiation of the combination arms in our Phase I/II CLAUDIO-01 trial represents an exciting clinical milestone in the development of SOT102 and our pursuit to provide novel and improved treatment options for patients suffering from solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The opportunity to evaluate SOT102 as part of a first-line treatment regimen will provide us valuable insights that could greatly expand the patient population who could benefit from this therapy.

“We look forward to collaborating with our clinical sites to carry out these studies as we work to deliver immunotherapies that can make a meaningful difference in the lives of patients with solid tumours.”

The company is advancing dose-finding studies in the trial’s monotherapy arm, where SOT102 will be used further in treating later-stage cancers.

SOT102 is an antibody-drug conjugate that combines target Claudin 18.2 with a powerful toxin to treat pancreatic, gastric and other cancers.